Sugi Predict

Sugi Predict / Targets / KCNJ6

KCNJ6

G protein-activated inward rectifier potassium channel 2 · P48051 · KCNJ6 on Sugi Atlas →

11,566 patent compounds predicted against KCNJ6, 5,174 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1010934 SCHEMBL1010934 0.63 18/20
SCHEMBL1013226 SCHEMBL1013226 0.61 18/20
SCHEMBL406623 SCHEMBL406623 0.51 17/20
SCHEMBL2243370 SCHEMBL2243370 0.56 16/20
SCHEMBL2247313 SCHEMBL2247313 0.56 16/20
SCHEMBL2243948 SCHEMBL2243948 0.55 16/20
SCHEMBL2243375 SCHEMBL2243375 0.55 16/20
SCHEMBL1780824 SCHEMBL1780824 0.65 15/20
SCHEMBL1012856 SCHEMBL1012856 0.58 15/20
SCHEMBL2240721 SCHEMBL2240721 0.58 15/20
SCHEMBL2240958 SCHEMBL2240958 0.56 15/20
SCHEMBL2247780 SCHEMBL2247780 0.55 15/20
SCHEMBL2081278 SCHEMBL2081278 0.45 15/20
SCHEMBL2245642 SCHEMBL2245642 0.60 14/20
SCHEMBL2243743 SCHEMBL2243743 0.58 14/20
SCHEMBL3176505 SCHEMBL3176505 0.56 14/20
SCHEMBL2243548 SCHEMBL2243548 0.49 14/20
SCHEMBL2243541 SCHEMBL2243541 0.47 14/20
SCHEMBL2082697 SCHEMBL2082697 0.46 14/20
SCHEMBL2242919 SCHEMBL2242919 0.55 13/20

Clinical trials — most relevant to KCNJ6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Long-Term Sulfonylurea Response in KCNJ11 Neonatal Diabetes PHASE4COMPLETED
Long-Term Sulfonylurea Response in ABCC8 Neonatal Diabetes (SuResponsSUR) PHASE4UNKNOWN
Effect of Methadone and Hydromorphone on the QT Interval After Anesthesia and Surgery PHASE4RECRUITING
Sulphonylurea Receptor Mutation and Responsiveness to Gliclazide - a Pilot Proof of Concept, Randomised Cross-over Study PHASE4COMPLETED
Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes PHASE4UNKNOWN
Mutation-specific Therapy for the Long QT Syndrome PHASE2COMPLETED
Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients PHASE2COMPLETED
Sandostatine® LP and Hyperinsulinism PHASE2COMPLETED
Evaluating Possible Improvement in Tinnitus Severity After 28 Days Dosing of the Study Drug AUT00063 Compared to Placebo PHASE2COMPLETED
Efficacy and Safety of AUT00063 Versus Placebo in Age-Related Hearing Loss PHASE2COMPLETED
Safety, Blood Levels and Effects of AUT00201 in Patients With MEAK PHASE1COMPLETED
Impact of Sulphonylureas on Neurodevelopmental Outcomes in KCNJ11-related Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome nanRECRUITING
The Physiological Effects of Human Ether-a-go-go-Related Gene (hERG)Blockade on Metabolism nanCOMPLETED
Evaluation of the Effects of KCNQ1 Mutation on Insulin Tolerance and Obsessive Compulsive Features in Long QT Romano-Ward Syndrome Patients. nanUNKNOWN
Macrolides for KCNJ5 - Mutated Aldosterone-Producing Adenoma (MAPA) nanUNKNOWN
Genetic Analysis of Heart Channelopathies in Brazilian Patients and Their Relatives nanUNKNOWN
Characteristics of Andersen-Tawil Syndrome nanCOMPLETED
Role of Nitric Oxide in Diabetic Patients With Erectile Dysfunction nanCOMPLETED
The Effects of the Anesthetic Drug Propofol on the Way the Heart Recovers Between Beats nanCOMPLETED
Role of KATP Channel Loss in Type 2 Diabetes nanRECRUITING
The Involvement of ATP Sensitive Potassium Channel in Migraine Aura and Migraine Pain. nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
The Effects of the Anti Nausea Drugs Droperidol and Ondansetron on the Way the Heart Recovers Between Beats nanCOMPLETED
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy nanUNKNOWN
Metabolism of Patients With Genetically Caused Cardiac Arrhythmia nanUNKNOWN
Specificities of Atypical Non AutoImmune Diabetes (ANAID) in the French West Indies nanNOT_YET_RECRUITING
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development nanCOMPLETED
Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy nanRECRUITING
CIQTP Prolongation : Role and Mechanism in Sudden Cardiac Death nanCOMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a KCNJ6 binder may also engage these)

ProteinNameSimilarity
P49658 — 1.000 P49658 →
P48542 — 1.000 P48542 →
Q5NVJ6 — 1.000 Q5NVJ6 →
P48550 — 1.000 P48550 →
P35561 — 0.994 P35561 →
O19182 — 0.993 O19182 →
P52185 — 0.993 P52185 →
P52186 — 0.992 P52186 →
P63253 — 0.992 P63253 →
Q9MYY9 — 0.991 Q9MYY9 →
Q4TZY1 — 0.991 Q4TZY1 →
KCNJ2 Inward rectifier potassium channel 2 0.991 landscape →
Q64273 — 0.991 Q64273 →
KCNJ3 G protein-activated inward rectifier potassium channel 1 0.991 landscape →
F1NHE9 — 0.991 F1NHE9 →
P49656 — 0.991 P49656 →
P48548 — 0.991 P48548 →
O18839 — 0.990 O18839 →
P48545 — 0.990 P48545 →
P63250 — 0.989 P63250 →
P63251 — 0.988 P63251 →
O02670 — 0.988 O02670 →
KCNJ5 G protein-activated inward rectifier potassium channel 4 0.988 landscape →
P52190 — 0.987 P52190 →
F1MYR9 — 0.987 F1MYR9 →
Q90854 — 0.987 Q90854 →
P52189 — 0.986 P52189 →
P52187 — 0.986 P52187 →
Q9NPI9 — 0.986 Q9NPI9 →
P52188 — 0.986 P52188 →